Kunle Odunsi
Overview
Explore the profile of Kunle Odunsi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
328
Citations
16871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dicks E, Tyrer J, Ezquina S, Jones M, Baierl J, Peng P, et al.
Eur J Hum Genet
. 2025 Feb;
33(3):297-303.
PMID: 39939714
Rare, germline loss-of-function variants in a handful of DNA repair genes are associated with epithelial ovarian cancer. The aim of this study was to evaluate the role of rare, coding,...
2.
Ricciuti J, Liu Q, Khan A, Joseph J, Veuskens B, Giridharan T, et al.
Gynecol Oncol
. 2025 Jan;
193:49-57.
PMID: 39764857
Purpose: We observed that the tumor microenvironment (TME) in metastatic epithelial ovarian cancer (EOC) and in other solid tumors can reprogram normal neutrophils to acquire a complement-dependent suppressor phenotype characterized...
3.
Rosario S, Long M, Chilakapati S, Gomez E, Battaglia S, Singh P, et al.
Nat Commun
. 2024 Dec;
15(1):10609.
PMID: 39638782
Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase...
4.
Kozbor D, Winkler M, Malhotra N, Mistarz A, Wang S, Hutson A, et al.
Res Sq
. 2024 Oct;
PMID: 39372930
The treatment-induced activation level within the perivascular tumor microenvironment (TME) that supports T-cell trafficking and optimal T-cell differentiation is unknown. We investigated the mechanisms by which inflammatory responses generated by...
5.
Dareng E, Coetzee S, Tyrer J, Peng P, Rosenow W, Chen S, et al.
Am J Hum Genet
. 2024 May;
111(6):1061-1083.
PMID: 38723632
To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981...
6.
Dicks E, Tyrer J, Ezquina S, Jones M, Baierl J, Peng P, et al.
medRxiv
. 2024 Apr;
PMID: 38633804
Rare, germline loss-of-function variants in a handful of genes that encode DNA repair proteins have been shown to be associated with epithelial ovarian cancer with a stronger association for the...
7.
Kurnit K, Odunsi K
Cold Spring Harb Perspect Med
. 2024 Apr;
14(12.
PMID: 38621830
Despite progress in other tumor types, immunotherapy is not yet part of the standard of care treatment for high-grade serous ovarian cancer patients. Although tumor infiltration by T cells is...
8.
Fadiel A, Eichenbaum K, Abbasi M, Lee N, Odunsi K
Sci Rep
. 2024 Apr;
14(1):7693.
PMID: 38565582
We have developed an innovative tool, the Intelligent Catchment Analysis Tool (iCAT), designed to identify and address healthcare disparities across specific regions. Powered by Artificial Intelligence and Machine Learning, our...
9.
Ndebele S, Turner T, Liao C, Aschebrook-Kilfoy B, Randorf N, Ahsan H, et al.
Int J Environ Res Public Health
. 2024 Feb;
21(2).
PMID: 38397711
(1) Objectives: To investigate the effect of individual-level, neighborhood, and environmental variables on uterine fibroid (UF) prevalence in a Chicago-based cohort. (2) Methods: Data from the Chicago Multiethnic Prevention and...
10.
Scalise C, Kincaid K, Thigpen H, Moore J, Dover B, Norian L, et al.
Gynecol Oncol
. 2024 Feb;
185:83-94.
PMID: 38377762
Objective: Advanced-stage high-grade serous ovarian cancer (HGSOC) remains a deadly gynecologic malignancy with high rates of disease recurrence and limited, effective therapeutic options for patients. There is a significant need...